State Street SPDR Bloomberg High Yield Bond ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.8 (market cap $5.86B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.65 (market cap $2.27B). The key difference: State Street SPDR Bloomberg High Yield Bond ETF is far larger — about 2.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNK | SLS | |
|---|---|---|
Market Cap | $5.86B | $2.27B |
Volume | 7,780,002 | 4,179,659 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $15.46 |
52-Week Low | $92.30 | $1.39 |
Typical Hold Time | 60 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.695 with a slight 0.07% decline, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions of $0.53 per share through mid-2026. Recent market focus centers on high-yield bond dynamics amid rising Treasury yields and institutional positioning changes.
The high-yield bond ETF faces headwinds from rising interest rates but benefits from institutional accumulation. Key risks include bond market volatility and economic sensitivity, while the consistent dividend stream provides income appeal for yield-seeking investors in the current rate environment.
No Aura AI signal available yet.
Trailing returns across standard periods
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →